Edith Mitchell
Medical Oncology · Philadelphia, PANPI 1639191984
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $138,878 of the $220,464 with a category attached, or 63.0%. 25 manufacturers reported payments, led by Genentech, Inc. at 27.0% of the total. Reporting peaked in 2022 at $62,141 and has fallen 99.0% since, to $651 in 2024. Among medical oncology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 160 payments — averaging $1377.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$59K
- E.r. Squibb & Sons, L.L.C.$20K
- Merck$16K
- Ipsen Biopharmaceuticals, Inc$15K
- Pfizer$14K
- Genentech USA, Inc.$13K
- plus $83K from 19 others
Across 23 payments — averaging $15,434 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Taiho Oncology, Inc.$309K
- AbbVie$23K
- Genentech, Inc.$18K
- Pfizer$4K
- F. Hoffmann-la Roche AG$1K
What the payments were for
- Consulting fees$138,87863%
- Speaking & faculty fees$60,58927%
- Grants$1,8801%
- Travel & lodging$14,0176%
- Food & beverage$5,0672%
- Education$330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 19 | $59,423 |
| E.r. Squibb & Sons, L.L.C. | 8 | $19,717 |
| Merck | 14 | $16,376 |
| Ipsen Biopharmaceuticals, Inc | 12 | $15,428 |
| Pfizer | 8 | $13,624 |
| Genentech USA, Inc. | 14 | $13,091 |
| Exelixis Inc. | 21 | $12,101 |
| Gilead | 4 | $10,588 |
| Bristol Myers Squibb | 8 | $10,438 |
| Taiho Oncology, Inc. | 4 | $10,054 |
| Janssen Research & Development, LLC | 18 | $8,149 |
| AstraZeneca | 1 | $6,508 |
| Array Biopharma Inc | 2 | $5,179 |
| Labcorp Holdings Inc. | 3 | $4,363 |
| GSK | 2 | $3,900 |
| Regeneron | 4 | $3,414 |
| G1 Therapeutics, Inc. | 3 | $2,699 |
| Bayer | 3 | $2,342 |
| Sanofi | 1 | $1,880 |
| Daiichi Sankyo Inc. | 6 | $504 |
| Foundation Medicine, Inc. | 1 | $229 |
| Angiodynamics, Inc. | 1 | $192 |
| Johnson & Johnson | 1 | $100 |
| Roche Molecular Systems, Inc. | 1 | $97 |
| Lilly USA, LLC | 1 | $68 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$220,464 in reported general payments places this provider in the 95th percentile of 238 medical oncology providers in Pennsylvania.
Other medical oncology in Philadelphia
- Carl JunePhiladelphia$9M
- Shayma KazmiPhiladelphia$619K
- Marcia BrosePhiladelphia$260K
- Adam CohenPhiladelphia$239K
- Daniel HallerPhiladelphia$227K
- Elizabeth PlimackPhiladelphia$190K
- Alexander PerlPhiladelphia$176K
- Martin EdelmanPhiladelphia$157K
- Jean-Pierre IssaPhiladelphia$147K
- Joshua BaumlPhiladelphia$144K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.